A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth

Cancer Letters

Volumn 281, Issue 1, 2009, Pages 8-23

  Bei, R ^a   Masuelli, L ^b   Palumbo, C ^a   Modesti, M ^c   Modesti, A ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti cancer immunity; Autoantibodies; Immune tolerance; Inflammation; Tumor antigens

Indexed keywords

ALPHA FETOPROTEIN ANTIBODY; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CD20 ANTIBODY; CENTROMERE PROTEIN B; COLLAGEN ANTIBODY; CYTOKERATIN ANTIBODY; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY; DNA ANTIBODY; DOUBLE STRANDED DNA; FIBRILLARIN; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; LA ANTIBODY; LA ANTIGEN; MONOPHENOL MONOOXYGENASE; PHOSPHOLIPID ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; PROTEIN P53; RO ANTIBODY; SINGLE STRANDED DNA; SM ANTIBODY; T LYMPHOCYTE RECEPTOR; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; TYROSINASE RELATED PROTEIN 1; TYROSINASE RELATED PROTEIN 2;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; COLON CANCER; DERMATOMYOSITIS; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; LUNG CANCER; MELANOMA; MIXED CONNECTIVE TISSUE DISEASE; NEOPLASM; PRIORITY JOURNAL; SHORT SURVEY; SJOEGREN SYNDROME; STOMACH CANCER; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TUMOR IMMUNITY;

EID: 67349267758     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.11.009     Document Type: Review

References (172)

1. Wardemann H., and Nussenzweig M.C. B-cell self-tolerance in humans. Adv. Immunol. 95 (2007) 83-110
2. Kyewski B., and Klein L. A central role for central tolerance. Annu. Rev. Immunol. 24 (2006) 571-606
3. Hogquist K.A., Baldwin T.A., and Jameson S.C. Central tolerance: learning self-control in the thymus. Nat. Rev. Immunol. 5 (2005) 772-782
4. Yurasov S., and Nussenzweig M.C. Regulation of autoreactive antibodies. Curr. Opin. Rheumatol. 19 (2007) 421-426
5. Kennedy R.C., and Shearer M.H. A role for antibodies in tumor immunity. Int. Rev. Immunol. 22 (2003) 141-172
6. Goodnow C.C., Sprent J., Fazekas de St. Groth B., and Vinuesa C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435 (2005) 590-597
7. Bei R., Masuelli L., Moriconi E., Visco V., Moretti A., Kraus M.H., and Muraro R. Immune responses to all ErbB family receptors detectable in serum of cancer patients. Oncogene 18 (1999) 1267-1275
8. Guerder S., and Flavell R.A. Costimulation in tolerance and autoimmunity. Int. Rev. Immunol. 13 (1995) 135-146
9. Plotz P.H. The autoantibody repertoire: searching for order. Nat. Rev. Immunol. 3 (2003) 73-78
10. Lohr J., Knoechel B., Nagabhushanam V., and Abbas A.K. T-cell tolerance and autoimmunity to systemic and tissue-restricted self-antigens. Immunol. Rev. 204 (2005) 116-127
11. Abu-Shakra M., Buskila D., Ehrenfeld M., Conrad K., and Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann. Rheum. Dis. 60 (2001) 433-440
12. Toubi E., and Shoenfeld Y. Protective autoimmunity in cancer (review). Oncol. Rep. 17 (2007) 245-251
13. Lu H., Goodell V., and Disis M.L. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J. Proteome Res. 7 (2008) 1388-1394
14. Ram M., and Shoenfeld Y. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?. Ann. NY Acad. Sci. 1110 (2007) 410-425
15. Bei R., Masuelli L., Trono P., Orvietani P.L., Losito S., Marzocchella L., Vitolo D., Albonici L., Mrozek M.A., Di Gennaro E., Lista F., Faggioni G., Ionna F., Binaglia L., Manzari V., Budillon A., and Modesti A. The ribosomal P0 protein induces a spontaneous immune response in patients with head and neck advanced stage carcinoma that is not dependent on its overexpression in carcinomas. Int. J. Oncol. 31 (2007) 1301-1308
16. Bei R., Budillon A., Reale M.G., Capuano G., Pomponi D., Budillon G., Frati L., and Muraro R. Cryptic epitopes on alpha-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients. Cancer Res. 59 (1999) 5471-5474
17. Zhang J.Y. Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma. Autoimmun. Rev. 6 (2007) 143-148
18. Livingston P.O., Ragupathi G., and Musselli C. Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues. J. Clin. Immunol. 20 (2000) 85-93
19. Ramirez-Montagut T., Turk M.J., Wolchok J.D., Guevara-Patino J.A., and Houghton A.N. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 22 (2003) 3180-3187
20. Moll J.W., Hooijkaas H., Goorbergh B.C., Roos L.G., Henzen-Logman S.C., and Vecht C.J. Systemic and anti-neuronal auto-antibodies in patients with paraneoplastic neurological disease. J. Neurol. 243 (1996) 51-56
21. Fernández-Madrid F., Karvonen R.L., Ensley J., Kraut M., Granda J.L., Alansari H., Tang N., and Tomkiel J.E. Spectra of antinuclear antibodies in patients with squamous cell carcinoma of the lung and of the head and neck. Cancer Detect. Prev. 29 (2005) 59-65
22. Torchilin V.P., Iakoubov L.Z., and Estov Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol. 22 (2001) 424-427
23. Stinton L.M., and Fritzler M.J. A clinical approach to autoantibody testing in systemic autoimmune rheumatic disorders. Autoimmun. Rev. 7 (2007) 77-84
24. Saif M.W., Zalonis A., and Syrigos K. The clinical significance of autoantibodies in gastrointestinal malignancies: an overview. Expert Opin. Biol. Ther. 7 (2007) 493-507
25. Lv S., Zhang J., Wu J., Zheng X., Chu Y., and Xiong S. Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice. Immunol. Lett. 99 (2005) 217-227
26. Brahms H., Raymackers J., Union A., de Keyser F., Meheus L., and Lührmann R. The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Sm autoantibodies. J. Biol. Chem. 275 (2000) 17122-17129
27. Franceschini F., and Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 38 (2005) 55-63
28. Atalay C., Atalay G., Yilmaz K.B., and Altinok M. The role of anti-CENP-B and anti-SS-B antibodies in breast cancer. Neoplasma 52 (2005) 32-35
29. Brendel V., Dohlman J., Blaisdell B.E., and Karlin S. Very long charge runs in systemic lupus erythematosus-associated autoantigens. Proc. Natl. Acad. Sci. USA 88 (1991) 1536-1540
30. Zhang L., Liu J., Zhang H., Wu S., Huang L., He D., and Xiao X. Discovery and identification of anti-U1-A snRNP antibody in lung cancer. Sci. China C Life Sci. 48 (2005) 641-647
31. Imai H., Ochs R.L., Kiyosawa K., Furuta S., Nakamura R.M., and Tan E.M. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am. J. Pathol. 140 (1992) 859-870
32. Ulanet D.B., Torbenson M., Dang C.V., Casciola-Rosen L., and Rosen A. Unique conformation of cancer autoantigen B23 in hepatoma: a mechanism for specificity in the autoimmune response. Proc. Natl. Acad. Sci. USA 100 (2003) 12361-12366
33. Briasoulis E., Kamposioras K., Tzovaras V., Pafitanis G., Kostoula A., Mavridis A., and Pavlidis N. CENP-B specific anti-centromere autoantibodies heralding small-cell lung cancer, a case study and review of the literature. Lung Cancer 60 (2008) 302-306
34. Chauhan R., Handa R., Das T.P., and Pati U. Over-expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes. Clin. Exp. Immunol. 136 (2004) 574-584
35. Soussi T. P53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60 (2000) 1777-1788
36. Fernández-Madrid F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett. 230 (2005) 187-198
37. Yamauchi T., Naoe T., Kurosawa Y., Shiku H., and Yamada K. Autoantibodies to c-myc nuclear protein products in autoimmune disease. Immunology 69 (1990) 117-120
38. Ben-Mahrez K., Sorokine I., Thierry D., Kawasumi T., Ishii S., Salmon R., and Kohiyama M. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int. J. Cancer 46 (1990) 35-38
39. Tan E.M., and Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol. Rev. 222 (2008) 328-340
40. Mahler M., Kessenbrock K., Raats J., Williams R., Fritzler M.J., and Blüthner M. Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J. Mol. Med. 81 (2003) 194-204
41. Castaneda J.A., and Pearce D.A. Identification of alpha-fetoprotein as an autoantigen in juvenile Batten disease. Neurobiol. Dis. 29 (2008) 92-102
42. Rezaei N., Gavalas N.G., Weetman A.P., and Kemp E.H. Autoimmunity as an aetiological factor in vitiligo. J. Eur. Acad. Dermatol. Venereol. 21 (2007) 865-876
43. Huang S.K., Okamoto T., Morton D.L., and Hoon D.S. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J. Invest. Dermatol. 111 (1998) 662-667
44. Nakanishi T., Takeuchi T., Ueda K., Murao H., and Shimizu A. Detection of eight antibodies in cancer patients' sera against proteins derived from the adenocarcinoma A549 cell line using proteomics-based analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 838 (2006) 15-20
45. Vernino S., and Lennon V.A. Autoantibody profiles and neurological correlations of thymoma. Clin. Cancer Res. 10 (2004) 7270-7275
46. Taplin C.E., and Barker J.M. Autoantibodies in type 1 diabetes. Autoimmunity 41 (2008) 11-18
47. Eck M., Schmausser B., Kerkau T., Greiner A., Kraus M., Fischbach W., and Müller-Hermelink H.K. Autoantibodies in gastric MALT-type lymphoma. Ann. Oncol. 14 (2003) 1153-1154
48. Sjöberg K., Roth E.B., Gustavsson L., Jönsson C., Simán H., Henriksson G., Stenberg P., Lindblom A., and Svensson P. Autoimmune markers in lymphoid malignancies. Scand. J. Immunol. 67 (2008) 509-515
49. Roth E.B., Stenberg P., Book C., and Sjoberg K. Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis-new pathways to epitope spreading. Clin. Exp. Rheumatol. 24 (2006) 12-18
50. Carroccio A., Iannitto E., Di Prima L., Cirrincione S., Troncone R., Paparo F., Trapani L.G., Gucciardi A., Averna M.R., Montalto G., and Notarbartolo A. Screening for celiac disease in non-Hodgkin's lymphoma patients: a serum anti-transglutaminase-based approach. Dig. Dis. Sci. 48 (2003) 1530-1536
51. Gómez-Puerta J.A., Cervera R., Espinosa G., Aguiló S., Bucciarelli S., Ramos-Casals M., Ingelmo M., Asherson R.A., and Font J. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin. Arthritis Rheum. 35 (2006) 322-332
52. Murota M., Nishioka M., Fujita J., Dobashi N., Wu F., Ohtsuki Y., Hojo S., Takahara J., and Kuriyama S. Anti-cytokeratin antibodies in sera of the patients with autoimmune hepatitis. Clin. Exp. Immunol. 125 (2001) 291-299
53. Ahlemann M., Schmitt B., Stieber P., Gires O., Lang S., and Zeidler R. Evaluation of CK8-specific autoantibodies in carcinomas of distinct localizations. Anticancer Res. 26 (2006) 783-789
54. Alard J.E., Dueymes M., Youinou P., and Jamin C. Modulation of endothelial cell damages by anti-Hsp60 autoantibodies in systemic autoimmune diseases. Autoimmun. Rev. 6 (2007) 438-443
55. Horváth L., Cervenak L., Oroszlán M., Prohászka Z., Uray K., Hudecz F., Baranyi E., Madácsy L., Singh M., Romics L., Füst G., and Pánczél P. Antibodies against different epitopes of heat-shock protein 60 in children with type 1 diabetes mellitus. Immunol. Lett. 80 (2002) 155-162
56. Desmetz C., Bibeau F., Boissière F., Bellet V., Rouanet P., Maudelonde T., Mangé A., and Solassol J. Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ. J. Proteome Res. 7 (2008) 3830-3837
57. Castelli M., Cianfriglia F., Manieri A., Palma L., Pezzuto R.W., Falasca G., and Delpino A. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity. Anticancer Res. 21 (2001) 753-758
58. Ripley B.J., Isenberg D.A., and Latchman DS D.S. Elevated levels of the 90 kDa heat shock protein (hsp90) in SLE correlate with levels of IL-6 and autoantibodies to hsp90. J. Autoimmun. 17 (2001) 341-346
59. Qin H.Y., Mahon J.L., Atkinson M.A., Chaturvedi P., Lee-Chan E., and Singh B.B. Type 1 diabetes alters anti-hsp90 autoantibody isotype. J. Autoimmun. 20 (2003) 237-245
60. Trieb K., Gerth R., Holzer G., Grohs J.G., Berger P., and Kotz R. Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy. Br. J. Cancer 82 (2000) 85-87
61. Meager A., Visvalingam K., Peterson P., Möll K., Murumägi A., Krohn K., Eskelin P., Perheentupa J., Husebye E., Kadota Y., and Willcox N. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 3 (2006) e289
62. Bei R., Masuelli L., Palumbo C., Tresoldi I., Scardino A., and Modesti A. Long-lasting tissue inflammatory processes trigger autoimmune responses to extracellular matrix molecules. Int. Rev. Immunol. 27 (2008) 137-175
63. Tong Y.Q., Zhang Z.J., Liu B., Huang J., Liu H., Liu Y., Guo F.J., Zhou G.H., Xie P.L., Li Y.H., Zuo C.H., Hu J.Y., and Li G.C. Autoantibodies as potential biomarkers for nasopharyngeal carcinoma. Proteomics 8 (2008) 3185-3193
64. Fernandez-Madrid F., Karvonen R.L., Kraut M.J., Czelusniak B., and Ager J.W. Autoimmunity to collagen in human lung cancer. Cancer Res. 56 (1996) 121-126
65. Adamson P.J., Zola H., Nicholson I.C., Pilkington G., and Hohmann A. Antibody against CD20 in patients with B cell malignancy. Leuk. Res. 25 (2001) 1047-1050
66. Nousari H.C., and Anhalt G.J. Pemphigus and bullous pemphigoid. Lancet 354 (1999) 667-672
67. Billet S.E., Grando S.A., and Pittelkow M.R. Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity 39 (2006) 617-630
68. Amagai M., Nishikawa T., Nousari H.C., Anhalt G.J., and Hashimoto T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J. Clin. Invest. 102 (1998) 775-782
69. de Beukelaar J.W., and Sillevis Smitt P.A. Managing paraneoplastic neurological disorders. Oncologist 11 (2006) 292-305
70. Racanelli V., Prete M., Minoia C., Favoino E., and Perosa F. Rheumatic disorders as paraneoplastic sindrome. Autoimmun. Rev. 7 (2008) 352-358
71. Ehrenfeld M., Abu-Shakra M., Buskila D., and Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol. Dis. 27 (2001) 750-756
72. Carl P.L., Temple B.R., and Cohen P.L. Most nuclear systemic autoantigens are extremely disordered proteins: implications for the etiology of systemic autoimmunity. Arthritis Res. Ther. 7 (2005) R1360-1374
73. James J.A., and Harley J.B. B-cell epitope spreading in autoimmunity. Immunol. Rev. 164 (1998) 185-200
74. Craft J., and Fatenejad S. Self antigens and epitope spreading in systemic autoimmunity. Arthritis Rheum. 40 (1997) 1374-1382
75. Deshmukh U.S., Bagavant H., Lewis J., Gaskin F., and Fu S.M. Epitope spreading within lupus-associated ribonucleoprotein antigens. Clin. Immunol. 117 (2005) 112-120
76. Nickerson C., Luthra H., and David C. Antigenic mimicry and autoimmune diseases. Int. Rev. Immunol. 7 (1991) 205-224
77. Oppenheim J.J., Dong H.F., Plotz P., Caspi R.R., Dykstra M., Pierce S., Martin R., Carlos C., Finn O., Koul O., and Howard O.M. Autoantigens act as tissue-specific chemoattractants. J. Leukoc. Biol. 77 (2005) 854-861
78. van den Boorn J.G., Le Poole I.C., and Luiten R.M. T-cell avidity, tuning The flexible connection between tolerance and autoimmunity. Int. Rev. Immunol. 25 (2006) 235-258
79. Nanda N.K., and Sercarz E.E. Induction of anti-self-immunity to cure cancer. Cell 82 (1995) 13-17
80. Zinkernagel R.M., and Hengartner H. Regulation of the immune response by antigen. Science 293 (2001) 251-253
81. Shlomchik M.J., Craft J.E., and Mamula M.J. From T to B and back again: positive feedback in systemic autoimmune disease. Nat. Rev. Immunol. 1 (2001) 147-153
82. Wang X.W., and Xie H. Alpha-fetoprotein enhances the proliferation of human hepatoma cells in vitro. Life Sci. 64 (1999) 17-23
83. Goldberg D.M., and Diamandis E.P. Models of neoplasia and their diagnostic implications: a historical perspective. Clin. Chem. 39 (1993) 2360-2374
84. Barnard G.F., Staniunas R.J., Mori M., Puder M., Jessup M.J., Steele Jr. G.D., and Chen L.B. Gastric and hepatocellular carcinomas do not overexpress the same ribosomal protein messenger RNAs as colonic carcinoma. Cancer Res. 53 (1993) 4048-4052
85. Kawakami Y., Robbins P.F., Wang R.F., Parkhurst M., Kang X., and Rosenberg S.A. The use of melanosomal proteins in the immunotherapy of melanoma. J. Immunother. 21 (1998) 237-246
86. Engelhard V.H., Altrich-Vanlith M., Ostankovitch M., and Zarling A.L. Post-translational modifications of naturally processed MHC-binding epitopes. Curr. Opin. Immunol. 18 (2006) 92-97
87. Anderton S.M. Post-translational modifications of self antigens: implications for autoimmunity. Curr. Opin. Immunol. 16 (2004) 753-758
88. Doyle H.A., Zhou J., Wolff M.J., Harvey B.P., Roman R.M., Gee R.J., Koski R.A., and Mamula M.J. Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity. J. Biol. Chem. 281 (2006) 32676-32683
89. Mamula M.J., Gee R.J., Elliott J.I., Sette A., Southwood S., Jones P.J., and Blier P.R. Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins. J. Biol. Chem. 274 (1999) 22321-22327
90. Terzoglou A.G., Routsias J.G., Avrameas S., Moutsopoulos H.M., and Tzioufas A.G. Preferential recognition of the phosphorylated major linear B-cell epitope of La/SSB 349-368 aa by anti-La/SSB autoantibodies from patients with systemic autoimmune diseases. Clin. Exp. Immunol. 144 (2006) 432-439
91. Matzinger P. The danger model: a renewed sense of self. Science 296 (2002) 301-305
92. Ullrich E., Bonmort M., Mignot G., Kroemer G., and Zitvogel L. Tumor stress, Cell death and the ensuing immune response. Cell Death Differ. 15 (2008) 21-28
93. Tesniere A., Panaretakis T., Kepp O., Apetoh L., Ghiringhelli F., Zitvogel L., and Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15 (2008) 3-12
94. Lorenz H.M., Herrmann M., Winkler T., Gaipl U., and Kalden J.R. Role of apoptosis in autoimmunity. Apoptosis 5 (2000) 443-449
95. Ramírez-Sandoval R., Sánchez-Rodríguez S.H., Herrera-van Oostdam D., Avalos-Díaz E., and Herrera-Esparza R. Antinuclear antibodies recognize cellular autoantigens driven by apoptosis. Joint Bone Spine 70 (2003) 187-194
96. Neufing P.J., Clancy R.M., Jackson M.W., Tran H.B., Buyon J.P., and Gordon T.P. Exposure and binding of selected immunodominant La/SSB epitopes on human apoptotic cells. Arthritis Rheum. 52 (2005) 3934-3942
97. Greidinger E.L., Foecking M.F., Magee J., Wilson L., Ranatunga S., Ortmann R.A., and Hoffman R.W. A major B cell epitope present on the apoptotic but not the intact form of the U1-70-kDa ribonucleoprotein autoantigen. J. Immunol. 172 (2004) 709-716
98. Zampieri S., Degen W., Ghiradello A., Doria A., and van Venrooij W.J. Dephosphorylation of autoantigenic ribosomal P proteins during Fas-L induced apoptosis: a possible trigger for the development of the autoimmune response in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 60 (2001) 72-76
99. Moudgil K.D., and Sercarz E.E. Understanding crypticity is the key to revealing the pathogenesis of autoimmunity. Trends Immunol. 26 (2005) 355-359
100. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity?. J. Exp. Med. 181 (1995) 1945-1948
101. Bockenstedt L.K., Gee R.J., and Mamula M.J. Self-peptides in the initiation of lupus autoimmunity. J. Immunol. 154 (1995) 3516-3524
102. Vanderlugt C.L., and Miller S.D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2 (2002) 85-95
103. McClain M.T., Lutz C.S., Kaufman K.M., Faig O.Z., Gross T.F., and James J.A. Structural availability influences the capacity of autoantigenic epitopes to induce a widespread lupus-like autoimmune response. Proc. Natl. Acad. Sci. USA 101 (2004) 3551-3556
104. Topfer F., Gordon T., and McCluskey J. Intra- and intermolecular spreading of autoimmunity involving the nuclear self-antigens La (SS-B) and Ro (SS-A). Proc. Natl. Acad. Sci. USA 92 (1995) 875-879
105. Madaio M.P., and Yanase K. Cellular penetration and nuclear localization of anti-DNA antibodies: mechanisms, consequences, implications and applications. J. Autoimmun. 11 (1998) 535-538
106. Tlsty T.D., and Coussens L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1 (2006) 119-150
107. Allavena P., Sica A., Solinas G., Porta C., and Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 66 (2008) 1-9
108. Lotfi R., Lee J.J., and Lotze M.T. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J. Immunother. 30 (2007) 16-28
109. Levesque M.C., and St. Clair E.W. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J. Allergy Clin. Immunol. 121 (2008) 13-21
110. Frisoni L., McPhie L., Colonna L., Sriram U., Monestier M., Gallucci S., and Caricchio R. Nuclear autoantigen translocation and autoantibody opsonization lead to increased dendritic cell phagocytosis and presentation of nuclear antigens: a novel pathogenic pathway for autoimmunity?. J. Immunol. 175 (2005) 2692-2701
111. Guo H., Leung J.C., Chan L.Y., Chan T.M., and Lai K.N. The pathogenetic role of immunoglobulin G from patients with systemic lupus erythematosus in the development of lupus pleuritis. Rheumatology (Oxford) 43 (2004) 286-293
112. Qing X., Zavadil J., Crosby M.B., Hogarth M.P., Hahn B.H., Mohan C., Gilkeson G.S., Bottinger E.P., and Putterman C. Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. Arthritis Rheum. 54 (2006) 2198-2210
113. Mantovani A., Romero P., Palucka A.K., and Marincola F.M. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371 (2008) 771-783
114. Munn D.H., and Mellor A.L. The tumor-draining lymph node as an immune-privileged site. Immunol. Rev. 213 (2006) 146-158
115. Kim R., Emi M., and Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 119 (2006) 254-264
116. Yanase K., and Madaio M.P. Nuclear localizing anti-DNA antibodies enter cells via caveoli and modulate expression of caveolin and p53. J. Autoimmun. 24 (2005) 145-151
117. Ruíz-Argüelles A., Pérez-romano B., Llorente L., Alarcón-Segovia D., and Castellanos J.M. Penetration of anti-DNA antibodies into immature live cells. J. Autoimmun. 11 (1998) 547-556
118. Rivadeneyra-Espinoza L., and Ruiz-Argüelles A. Cell-penetrating anti-native DNA antibodies trigger apoptosis through both the neglect and programmed pathways. J. Autoimmun. 26 (2006) 52-56
119. Lang B., Pinto A., Giovannini F., Newsom-Davis J., and Vincent A. Pathogenic autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann. NY Acad. Sci. 998 (2003) 187-195
120. Kozyr A.V., Kolesnikov A.V., Aleksandrova E.S., Sashchenko L.P., Gnuchev N.V., Favorov P.V., Kotelnikov M.A., Iakhnina E.I., Astsaturov I.A., Prokaeva T.B., Alekberova Z.S., Suchkov S.V., and Gabibov A.G. Novel functional activities of anti-DNA autoantibodies from sera of patients with lymphoproliferative and autoimmune diseases. Appl. Biochem. Biotechnol. 75 (1998) 45-61
121. Sioud M. How does autoimmunity cause tumor regression? A potential mechanism involving cross-reaction through epitope mimicry. Mol. Med. 8 (2002) 115-119
122. Reichlin M. Cellular dysfunction induced by penetration of autoantibodies into living cells: cellular damage and dysfunction mediated by antibodies to dsDNA and ribosomal P proteins. J. Autoimmun. 11 (1998) 557-561
123. Alarcón-Segovia D., Llorente L., Fishbein E., and Díaz-Jouanen E. Abnormalities in the content of nucleic acids of peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum. 25 (1982) 304-317
124. Sun K.H., Yu C.L., Tang S.J., and Sun G.H. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis. Immunology 99 (2000) 352-360
125. Deshmukh U.S., Bagavant H., and Fu S.M. Role of anti-DNA antibodies in the pathogenesis of lupus nephritis. Autoimmun. Rev. 5 (2006) 414-418
126. Ruiz-Argüelles A., Rivadeneyra-Espinoza L., and Alarcón-Segovia D. Antibody penetration into living cells: pathogenic, preventive and immuno-therapeutic implications. Curr. Pharm. Des. 9 (2003) 1881-1887
127. Reichlin M. Cell injury mediated by autoantibodies to intracellular antigens. Clin. Immunol. Immunopathol. 76 (1995) 215-219
128. Miranda-Carús M.E., Boutjdir M., Tseng C.E., DiDonato F., Chan E.K., and Buyon J.P. Induction of antibodies reactive with SSA/Ro-SSB/La and development of congenital heart block in a murine model. J. Immunol. 161 (1998) 5886-5892
129. Muro Y., Matsumoto Y., and Ohashi M. Anticentromere-protein-B-DNA complex activities in anticentromere antibody-positive patients. Arch. Dermatol. Res. 284 (1992) 396-399
130. Zusman I. Comparative anticancer effects of vaccination and dietary factors on experimentally-induced cancers. In Vivo 12 (1998) 675-689
131. Tendler Y., Ben-Hur H., Gurevich P., Berman V., Sandler B., Nyska A., Zion H., Zinder O., and Zusman I. Role of apoptosis proliferating cell nuclear antigen and p53 protein in the immune response of rat colon cells to cancer and vaccination with anti-p53 polyclonal antibodies. Anticancer Res. 17 (1997) 4653-4657
132. Hara T., Ogawa F., Muroi E., Komura K., Takenaka M., Hasegawa M., Fujimoto M., and Sato S. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis. J. Rheumatol. 35 (2008) 451-457
133. Herkel J., Mimran A., Erez N., Kam N., Lohse A.W., Märker-Hermann E., Rotter V., and Cohen I.R. Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies. J. Autoimmun. 17 (2001) 63-69
134. Gardner-Thorpe J., Ito H., Ashley S.W., and Whang E.E. Autoantibody-mediated inhibition of pancreatic cancer cell growth in an athymic (nude) mouse model. Pancreas 27 (2003) 180-189
135. Matus S., Burgos P.V., Bravo-Zehnder M., Kraft R., Porras O.H., Farías P., Barros L.F., Torrealba F., Massardo L., Jacobelli S., and González A. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J. Exp. Med. 204 (2007) 3221-3234
136. Mizejewski G.J., and Vonnegut M. Characteristics of the androgenization produced in mice by neonatal exposure to alpha-fetoprotein antibodies. Teratology 25 (1982) 351-360
137. Kemp E.H., Gavalas N.G., Gawkrodger D.J., and Weetman A.P. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun. Rev. 6 (2007) 138-142
138. López-Alemany R., Longstaff C., Hawley S., Mirshahi M., Fábregas P., Jardí M., Merton E., Miles L.A., and Félez J. Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-enolase. Am. J. Hematol. 72 (2003) 234-242
139. Magrys A., Anekonda T., Ren G., and Adamus G. The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy. J. Clin. Immunol. 27 (2007) 181-192
140. Karanikas G., Schuetz M., Wahl K., Paul M., Kontur S., Pietschmann P., Kletter K., Dudczak R., and Willheim M. Relation of anti-TPO autoantibody titre and T-lymphocyte cytokine production patterns in Hashimoto's thyroiditis. Clin. Endocrinol. (Oxf.) 63 (2005) 191-196
141. Salmon J.E., and de Groot P.G. Pathogenic role of antiphospholipid antibodies. Lupus 17 (2008) 405-411
142. Codignola A., Tarroni P., Clementi F., Pollo A., Lovallo M., Carbone E., and Sher E. Calcium channel subtypes controlling serotonin release from human small cell lung carcinoma cell lines. J. Biol. Chem. 268 (1993) 26240-26247
143. Lang B., Pinto A., Giovannini F., Newsom-Davis J., and Vincent A. Pathogenic autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann. NY Acad. Sci. 998 (2003) 187-195
144. Yokota S., Minota S., and Fujii N. Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via toll-like receptors. Int. Immunol. 18 (2006) 573-580
145. Mandal K., Foteinos G., Jahangiri M., and Xu Q. Role of antiheat shock protein 60 autoantibodies in atherosclerosis. Lupus 14 (2005) 742-746
146. Tomer Y. Anti-thyroglobulin autoantibodies in autoimmune thyroid diseases: cross-reactive or pathogenic?. Clin. Immunol. Immunopathol. 82 (1997) 3-11
147. Atta M.S., Powell R.J., and Todd I. The influence of anti-fibronectin antibodies on interactions involving extracellular matrix components and cells: a possible pathogenic mechanism. Clin. Exp. Immunol. 96 (1994) 26-30
148. Riente L., Marchini B., Dolcher M.P., Puccetti A., Bombardieri S., and Migliorini P. Anti-collagen antibodies in systemic sclerosis and in primary Raynaud's phenomenon. Clin. Exp. Immunol. 102 (1995) 354-359
149. Vlahakos D.V., Foster M.H., Ucci A.A., Barrett K.J., Datta S.K., and Madaio M.P. Murine monoclonal anti-DNA antibodies penetrate cells bind to nuclei and induce glomerular proliferation and proteinuria in vivo. J. Am. Soc. Nephrol. 2 (1992) 1345-1354
150. Sun K.H., Tang S.J., Lin M.L., Wang Y.S., Sun G.H., and Liu W.T. Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture. Rheumatology (Oxford) 40 (2001) 750-757
151. Sun K.H., Liu W.T., Tang S.J., Tsai C.Y., Hsieh S.C., Wu T.H., Han S.H., and Yu C.L. The expression of acidic ribosomal phosphoproteins on the surface membrane of different tissues in autoimmune and normal mice which are the target molecules for anti-double-stranded DNA antibodies. Immunology 87 (1996) 362-371
152. Vachtenheim J., Duchon J., Matous B., and Vulterin K. Specific inhibition by antityrosinase antibodies of tyrosinase-mediated melanogenesis. J. Invest. Dermatol. 86 (1986) 573-576
153. Thurber G.M., Schmidt M.M., and Wittrup K.D. Factors determining antibody distribution in tumors. Trends Pharmacol. Sci. 29 (2008) 57-61
154. Syrigos K.N., Charalambopoulos A., Pliarchopoulou K., Varsamidakis N., Machairas A., and Mandrekas D. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 20 (2000) 4351-4353
155. Fernández-Madrid F., VandeVord P.J., Yang X., Karvonen R.L., Simpson P.M., Kraut M.J., Granda J.L., and Tomkiel J.E. Antinuclear antibodies as potential markers of lung cancer. Clin. Cancer Res. 5 (1999) 1393-1400
156. Blaes F., Klotz M., Huwer H., Straub U., Kalweit G., Schimrigk K., and Schäfers H.J. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann. Thorac. Surg. 69 (2000) 254-258
157. Wasserman J., Glas U., and Blomgren H. Autoantibodies in patients with carcinoma of the breast. Correlation with prognosis. Clin. Exp. Immunol. 19 (1975) 417-422
158. Gumus E., Erdamar S., Demirel G., Horasanli K., Kendirci M., and Miroglu C. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int. J. Urol. 11 (2004) 1070-1077
159. Hofele C., Schwager-Schmitt M., and Volkmann M. Prognostic value of antibodies against p53 in patients with oral squamous cell carcinoma-five years survival rate. Laryngorhinootologie 81 (2002) 342-345
160. Mack U., Ukena D., Montenarh M., and Sybrecht G.W. Serum anti-p53 antibodies in patients with lung cancer. Oncol. Rep. 7 (2000) 669-674
161. Kallenberg C.G., Stegeman C.A., Bootsma H., Bijl M., and Limburg P.C. Quantitation of autoantibodies in sistemi autoimmune diseases: clinically useful?. Lupus 15 (2006) 397-402
162. Praprotnik S., Bozic B., Kveder T., and Rozman B. Fluctuation of anti-Ro/SS-A antibody levels in patients with systemic lpus erythematosus and Sjögren's syndrome: a prospective study. Clin. Exp. Rheumatol. 17 (1999) 63-68
163. Hammel P., Leroy-Viard K., Chaumette M.T., Villaudy J., Falzone M.C., Rouillard D., Hamelin R., Boissier B., and Remvikos Y. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int. J. Cancer 81 (1999) 712-718
164. Zalcman G., Schlichtholz B., Trédaniel J., Urban T., Lubin R., Dubois I., Milleron B., Hirsch A., and Soussi T. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. Clin. Cancer Res. 4 (1998) 1359-1366
165. Mitsudomi T., Suzuki S., Yatabe Y., Nishio M., Kuwabara M., Gotoh K., Hatooka S., Shinoda M., Suyama M., Ogawa M., Takahashi T., Ariyoshi Y., and Takahashi T. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. J. Natl. Cancer Inst. 90 (1998) 1563-1568
166. Gottschlich S., Hoffmann M., Maass J.D., Görörgh T., Buhmann V., Hoffmann-Fazel A., Rudert H., and Maune S. P53 autoantibodies as tumor marker in head and neck squamous cell cancer. Anticancer Res. 23 (2003) 913-915
167. Metcalfe S., Wheeler T.K., Picken S., Negus S., and Jo Milner A. P53 autoantibodies in 1006 patients followed up for breast cancer. Breast Cancer Res. 6 (2000) 438-443
168. Chapman C., Murray A., Chakrabarti J., Thorpe A., Woolston C., Sahin U., Barnes A., and Robertson J. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann. Oncol. 18 (2007) 868-873
169. Li Y., Karjalainen A., Koskinen H., Hemminki K., Vainio H., Shnaidman M., Ying Z., Pukkala E., and Brandt-Rauf P.W. P53 autoantibodies predict subsequent development of cancer. Int. J. Cancer 114 (2005) 157-160
170. Homma S., Sagawa Y., Ito M., Ohno T., and Toda G. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin. Exp. Immunol. 144 (2006) 41-47
171. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., Panagiotou P., Polyzos A., Papadopoulos O., Stratigos A., Markopoulos C., Bafaloukos D., Pectasides D., Fountzilas G., and Kirkwood J.M. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354 (2006) 709-718
172. Pardoll D.M. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA 96 (1999) 5340-5342